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Abstract
Background: Fatty liver disease (FLD), primarily nonalcoholic fatty liver disease 
(NAFLD), is the most common liver disorder that affects a quarter of the global popu-
lation. NAFLD is a spectrum of disease ranging from simple steatosis to nonalcoholic 
steatohepatitis, which is associated with increased risk of developing liver cancer. Given 
that the pathogenic mechanisms of fatty liver remain largely elusive, it is important to 
further investigate potential underlying mechanisms including epigenetic modifications. 
Here, we performed a systematic review of human epigenetic studies on FLD presence.
Methods: Five bibliographic databases were screened until 28 August 2020. We in-
cluded cross-sectional, case-control and cohort studies in humans that examined the 
association of epigenetic modifications including global, candidate or epigenome-
wide methylation of DNA, noncoding RNAs and histone modifications with FLD.
Results: In total 36 articles, based on 33 unique studies, consisting of 12 112 par-
ticipants met the inclusion criteria. Among these, two recent epigenome-wide as-
sociation studies conducted among large population-based cohorts have reported the 
association between cg06690548 (SLC7A11) and FLD. Moreover, several studies 
have demonstrated the association between microRNAs (miRNAs) and FLD, in 
which miR-122, miR-34a and miR-192 were recognized as the most relevant miR-
NAs as biomarkers for FLD. We did not find any studies examining histone modifi-
cations in relation to FLD.
Conclusions: Cumulative evidence suggests a link between epigenetic mechanisms, 
specifically DNA methylation and miRNAs, and FLD. Further efforts should inves-
tigate the molecular pathways by which these epigenetic markers may regulate FLD 
and also the potential role of histone modifications in FLD.
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1 |  INTRODUCTION
Fatty liver disease (FLD), also called hepatic steatosis, is de-
fined as intrahepatic fat of at least 5% of liver weight. The 
majority of fatty liver patients develop nonalcoholic fatty liver 
disease (NAFLD), which is the most common cause of chronic 
liver disease worldwide. Currently, the prevalence is about 
25% of the global population with the highest burden among 
Middle Eastern and South American countries.1 NAFLD is a 
spectrum of disease ranging from simple steatosis, which has 
a negligible risk of progression to cirrhosis, to nonalcoholic 
steatohepatitis (NASH), which has an increased risk of pro-
gression to cirrhosis and eventually liver cancer.2 The molec-
ular mechanisms underlying these processes are not entirely 
understood. Further investigations that could provide a better 
understanding of the disease pathogenic mechanisms are im-
portant to improve early diagnosis and treatment of FLD.
The pathogenesis of FLD is multifactorial. Exposure to 
particular environmental factors lifestyle habits, nutritional 
factors and genetics are thought to influence the disease risk, 
progression and prognosis. Emerging evidence suggests that 
epigenetic modifications may also contribute to the patho-
physiology of FLD.3 Epigenetics including DNA methylation, 
histone modifications and noncoding RNAs refers to stable 
and heritable alterations in regulating gene expression, inde-
pendent of changes in the DNA sequence.4 Among noncod-
ing RNAs, microRNAs (miRNAs), the small noncoding RNA 
molecules that regulate gene expression at the post-transcrip-
tional level, are the most extensively studied epigenetic mark-
ers in regard to FLD risk.5 Many studies have explored the role 
of miRNAs in the pathogenesis of FLD and their potential as 
biomarkers of the disease, but the results are sometimes incon-
sistent.6-9 Long noncoding RNAs (lncRNAs) are a group of 
RNA molecules longer than 200 bases without protein-coding 
capacity, involved in chromatin remodelling, as well as tran-
scriptional and post-transcriptional gene regulation.10 They 
have been mainly studied in mouse models of NAFLD or 
NASH with a few studies conducted in human. DNA methyl-
ation is another important epigenetic mechanism that has been 
suggested to contribute to the pathophysiology of fatty liver 
disease.4 The three most common approaches to investigate 
the association of DNA methylation signatures with a trait of 
interest are global DNA methylation, candidate gene approach 
and epigenome-wide association studies (EWAS). Unlike ge-
netic variation, epigenetic modifications comprise dynamic 
changes and potentially reversible; therefore, it could be mod-
ified by lifestyle and other therapeutic approaches.
Previous studies have summarized the evidence pertain-
ing epigenetic mechanisms and FLD.5,11 However, these 
studies mainly focused on individual epigenetic mechanism, 
and therefore a comprehensive assessment of other epigene-
tic modifications such as DNA methylation, histone modifi-
cations present in FLD is currently lacking. Thus, this study 
aimed to conduct a systematic review of the current evidence 
in human studies to comprehensively evaluate the association 
between epigenetic modifications and FLD.
2 |  METHODS
2.1 | Data sources and search strategies
This systematic review was conducted using a predesigned 
protocol and was reported in accordance with PRISMA12 
guidelines (Table S1). The studies published until 28 August 
2020 (date last searched) were searched in five bibliographic 
databases: Embase.com, Medline ALL (Ovid), Web of 
Science Core Collection, Cochrane Central Register of trials 
and Google scholar. The search was performed by an experi-
enced medical information specialist (WMB). In Embase.com 
and Medline (Ovid) databases, articles were searched by the-
saurus terms, title and/or abstract; in other databases, only by 
title and/or abstract. The search combined terms related to the 
exposure (eg epigenetics, DNA methylation, histone modifi-
cations, noncoding RNAs and microRNAs) and outcome (eg 
fatty liver, NAFLD, alcoholic liver disease, nonalcoholic and 
NASH). The search was restricted only to studies conducted 
on humans. The full search strategy is provided in Table S2.
2.2 | Study selection and inclusion criteria
Studies were eligible for inclusion if they (a) were cross-sec-
tional, case-control or cohort studies; (b) assessed epigenetic 
marks (global, candidate gene studies or epigenome-wide 
analysis methylation of DNA, noncoding RNAs, miRNAs 
or histone modifications); (c) were conducted in humans; (d) 
collected data on FLD (fatty liver disease, NAFLD, hepatic 
steatosis, hepatic fat, simple steatosis and NASH) and (e) re-
ported the association of any of the above-mentioned epige-
netic marks with FLD.
We screened the retrieved titles and abstracts and se-
lected eligible studies according to the predefined selection 
criteria (Table  S3). The full texts of the selected records 
which satisfied selection criteria were obtained and exam-
ined further by two researchers (XZ and EA). In case of 
disagreement, decision was made through consensus or 
consultation with a third independent reviewer (MA). Full 
texts were retrieved for studies that satisfied all selection 
criteria.
2.3 | Data extraction and quality assessment
Data extraction and quality assessment were indepen-
dently conducted by two researchers (XZ and EA) using a 
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predesigned form. The form included information on study 
authors, publication date, population groups with mean 
age, sample sizes, geographical location, study design, out-
come, tissue type, adjustments/ matching, main findings 
and quality of study. Potential bias within each individual 
study was evaluated by two independent reviewers (XZ and 
EA) using the validated Newcastle-Ottawa Scale (NOS),13 
a semi-quantitative scale designed to evaluate the quality 
of case-control or cohort studies. We evaluated cross-sec-
tional studies using an adapted version of the scales. Study 
quality was judged based on these items: the selection cri-
teria of participants, comparability of cases and controls, 
and exposure and outcome assessments. The NOS assigns 
a maximum of 4 points for selection, 2 points for compara-
bility and 3 points for exposure or outcome, with 9 points 
referring to highest quality of the study and to be at low 
risk of bias. Studies scoring 1-3 were defined as low, 4-6 
as average and 7-9 as high quality.
3 |  RESULTS
As shown in Figure 1, 7813 potentially relevant records were 
identified from five databases. After removing duplicates, 
4423 records were retained. Of these, 4289 records were ex-
cluded based on titles and abstracts. For the remaining 134 
records, full-text articles were reviewed, 98 of which were 
excluded for various reasons as described in Figure 1. A total 
of 36 articles met the eligibility criteria and were included 
in this review. In the following section, a summary of all the 
F I G U R E  1  Flow chart of studies included in the systematic review
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T A B L E  1  Overview of included studies on DNA methylation and fatty liver disease




Country Study design Outcome Measurement method Tissue type Adjustment level/Matching Main findings
Study 
qualitya 
Global DNA methylation and fatty liver disease
Pirola et al, 201316 49.4,
n = 63,
Argentina
Case-control NAFLD and 
NASH
Methylation-specific PCR  
and liver biopsy
Liver tissue None MT-ND6 methylation was higher in the liver of NASH than 
simple steatosis patients (P < .04) and the methylation 
level of MT-ND6was significantly associated with NAFLD 
activity score (P < .02).
6
Mello et al, 201717 49.5,
n = 95,
Finland
Cross-sectional NAFLD and 
NASH
LINE-1 DNA methylation,  
Bisulphite pyrosequencing  
and liver biopsy
Liver tissue BMI, age, sex and T2D NASH was associated with LINE-1 hypomethylation 
compared with simple steatosis or normal liver.
8
Lead Author, Year of 
publication
Mean age, Sample size, 
Country Study design Outcome
Methylation sites,  
Measurement method Tissue type Adjustment level/ Matching Main findings
Study 
qualitya 
Candidate gene approach and fatty liver disease
Sookoian et al, 201018 50.2,
n = 74,
Argentina
Case-control NAFLD Methylation-specific PCR  
and liver biopsy
Blood and liver 
tissue
HOMA-IR The liver mtDNA/nDNA ratio was significantly higher in 
control livers compared with NAFLD livers. mtDNA/nDNA 
ratio was inversely correlated with PPARGC1A promoter 
methylation.
7
Kordi-Tamandani et al, 201119 39.2,
n = 160,
Iran
Case-control NAFLD GSTT1 and GSTP1,  




None No association between methylation status and expression 
profiles of GSTT1 and GSTP1 genes and NAFLD.
6
Murphy et al, 201320 51.2,
n = 90,
USA
Cohort NAFLD FGFR2, MAT1A, and CASP1,  
Bisulphite pyrosequencing  
and liver biopsy
Liver tissue None Most of differentially methylated CpG sites were 
hypomethylated in obese patients with advanced vs mild 
NAFLD. Methylation at FGFR2, MAT1A and CASP1 was 
validated in a replication cohort.
6
Kitamoto et al, 201521 53.7,
n = 95,
Japan
Cohort NAFLD PNPLA3, SAMM50, and  
PARVB, Targeted-bisulphite  
sequencing and liver biopsy
Liver tissue None PARVB was hypomethylated in the livers of patients with 
advanced NAFLD, PNPLA3 was hypermethylated in these 
patients. The levels of SAMM50 mRNA did not differ 
between patients with mild or advanced NAFLD.
6
Lead Author, Year of 
publication
Mean age, Sample size, 
Country Study design Outcome
Methylation sites,  
Measurement method Tissue type Adjustments/Matching Main findings
Study 
qualitya 
Zeybel et al, 201522 59.9,
n = 34,
UK
Cross-sectional NAFLD PPARα, TGFβ1,  
Collagen 1A1 and PDGFα,  
Bisulphite pyrosequencing  
and liver biopsy
Liver tissue None DNA methylation at specific CpG sites within genes known to 
affect fibrogenesis distinguishes between patients with mild 
severe fibrosis in NAFLD.
6
Epigenome-wide association studies and fatty liver disease
Hotta et al, 201725 51.1,
n = 60,
Japan
Cohort NAFLD Illumina Infinium
Human Methylation 450  
BeadChip and liver biopsy
Liver tissue None four hub genes (PAPLN, LBH, DPYSL3, and JAG1) 
overexpressed in advanced NAFLD.
6
Mwinyi et al, 201724 51.0,
n = 178,
Sweden
Cohort NAFLD Illumina Human Methylation  
450 Beadchip and liver  
biopsy
Liver tissue Gender, age, BMI and liver disease state NAFLD is associated with methylation shifts with relevance 
for the expression of NPC1L1, STARD and GRHL involved in 
lipoprotein particle composition.
8
Nano et al, 201723 63.5,
n = 1450,
The Netherlands
Cohort Hepatic steatosis Illumina Human Methylation  
450K array and ultrasound
Whole blood 
samples
Age, sex, cohort, lifestyle factors, BMI, 
hypertension, triglycerides, HDL, glucose 
level, liver enzyme levels.
DNA methylation at cg06690548 (SLC7A11) was associated 
with reduced risk of hepatic steatosis in participants (odd 
ratio, 0.69; 95%CI = 0.55-0.93; P-value = 2.7 × 10−3)
8
Ma et al, 201914 61.2,
n = 4525,
USA and the Netherlands
Cross-sectional and cohort Hepatic fat and 
NAFLD
Illumina Infinium Human  
Methylation 450 (450K)  




Age, sex, smoking status, physical activity 
levels, and alcohol intake and BMI
22 CpGs associated with hepatic fat in European ancestry 
participants. Mendelian randomization analyses supported the 
association of hypomethylation of cg08309687 (LINC00649) 
with NAFLD (P = 2.5 × 10−4).
8
Abbreviations: BMI, body mass index; CT, computed tomography; HDL, high-density lipid; HOMA-IR, homeostatic model assessment-insulin resistance; LINE,  
Long-interspersed nuclear element; mtDNA, mitochondrial DNA; MT-ND6, mitochondrially encoded NADH dehydrogenase 6; NAFLD, nonalcoholic fatty liver  
disease; NASH, nonalcoholic steatohepatitis;nDNA, nuclear DNA; PCR, polymerase chain reaction; T2D, type 2 diabetes.
aQuality assessment based on the Newcastle-Ottawa Scale. Range 0-9, higher score is higher quality. 
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included studies is provided, followed by a review of their 
findings. Results are presented for DNA methylation (includ-
ing the global, candidate gene analysis and EWAS approach) 
and noncoding RNAs (miRNAs and lncRNAs).
3.1 | Summary of included studies
Of the 36 included publications (33 unique studies), two stud-
ies assessed global DNA methylation, five studies assessed 
DNA methylation for specific candidate genes and four stud-
ies used the EWAS approach. Moreover, 24 studies inves-
tigated miRNAs and one studied lncRNAs. There were no 
studies examining histone modifications in relation to FLD.
A total of 12 112 individuals were involved in all the stud-
ies. The mean age across all studies was 48.8 years and in-
cluded participants from Asian (n = 13), European (n = 11), 
North American (n = 7), South American (n = 4) ancestries 
and one study included subjects from both European and 
North American ancestries.14 Overall, the study designs were 
as follows: cohort (n = 16), case-control (n = 10), cross-sec-
tional (n = 9) and one study including both a cross-sectional 
and a prospective cohort design. Epigenetic signatures were 
measured in liver tissue (n = 10), blood samples (n = 16) and 
both liver and blood (n = 10). The studies included in this 
review diagnosed FLD based on two different methods: mea-
sured by liver biopsy (n = 19) or by imaging (including ultra-
sonography, liver magnetic resonance imaging and computed 
tomography) (n = 17). The majority of articles focused on 
miRNAs and NAFLD mainly used qPCR-based methods to 
measure the expression levels of miRNAs, while fewer used 
next-generation sequencing. Most of the candidate gene DNA 
methylation studies used bisulphite pyrosequencing, a quan-
titative approach with high reproducibility, but with relatively 
short length of reads.15 The most commonly platform used 
in the EWAS publications was the Illumina Infinium Human 
Methylation 450 Bead Chip, which enabled the screening of 
over 450 000 CpGs with high quantitative accuracy. Detailed 
characteristics of the 36 included studies are summarized in 
Tables 1 and 2.
3.2 | DNA methylation
3.2.1 | Global DNA methylation studies
Two studies16,17 examined the association between global 
DNA methylation and FLD (Table  1). One study16 con-
ducted among South American participants (normal livers 
[n = 18], simple steatosis [n = 23] and NASH [n = 22]) used 
liver tissue samples to evaluate the status of cytosine meth-
ylation at the 5mC of liver mitochondrial DNA (mtDNA) in 
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that mitochondrial encoded NADH dehydrogenase 6 (MT-
ND6) methylation was higher in the liver of NASH than 
participants with simple steatosis (P <  .04). Moreover, the 
methylation level of MT-ND6 was significantly associated 
with NAFLD activity score which was used to evaluate the 
spectrum of NAFLD (P < .02). The other study17 conducted 
among 95 European participants reported that global liver 
methylation based on genome-wide methylation arrays was 
not associated with NAFLD nor NASH. However, when as-
sessed by long-interspersed nuclear element (LINE-1) meth-
ylation levels, liver global DNA methylation was associated 
with hypomethylation among participants with NASH as 
compared to those with NAFLD or healthy controls.
3.2.2 | Candidate-based DNA 
methylation studies
Five studies18-22 examined the relation of FLD with meth-
ylation sites in or near candidate genes (Table 1). Overall, 
these studies reported that methylated CpG sites annotated 
to PPARGC1A, TFAM, FGFR2, MAT1A, CASP1, PARVB, 
PNPLA3, PPARα, TGFβ1, Collagen 1A1, PDGFα, PAPLN, 
LBH, DPYSL3, JAG1, NPC1L1, STARD and GRHL are as-
sociated with FLD. An overview of these genes, the asso-
ciation with FLD and function is provided in Table S4. Of 
these, one study19 was performed only in peripheral blood 
samples, three studies20-22 only used liver tissue samples and 
one study18 used both blood and liver tissue samples. Two 
studies used the bisulphite pyrosequencing method,20,22 two 
other studies used methylation-specific polymerase chain re-
action,18,19 and one study used targeted-bisulphite sequenc-
ing to quantify DNA methylation.21 The majority (n = 4) of 
these studies reported adjustment or control for confounders.
The five studies performed a candidate gene approach and 
there was no any overlap between them. These studies found 
that NAFLD was associated with hypomethylation at FGFR2, 
MAT1A, CASP120 and PARVB genes21 and hypermethylation 
at PNPLA3,21 PPARα, TGFβ1, Collagen 1A1 and PDGFα 
genes.22 One additional study18 found that PPARGC1A meth-
ylation status was significantly associated with NAFLD, 
and 47.9% of alleles were methylated in participants with 
NAFLD vs 30.6% in healthy controls (P < .01). In addition, 
no association was found between the methylation status of 
GSTT1, GSTP119 and SAMM50 genes21 and NAFLD.
3.2.3 | Epigenome-wide DNA 
methylation studies
Four studies examined the association between DNA methyla-
tion and FLD using an EWAS approach. All these studies used 
illumina Human Methylation 450 (450K) Beadchip to quantify 
DNA methylation. Two studies14,23 used whole blood samples, 
and the other two studies24,25 were performed in liver tissue. 
Three studies14,23,24 adjusted for potential confounders and only 
one study25 did not adjust for any confounders. Two of these 
studies conducted very recently14,23 reported an association be-
tween cg06690548 (SLC7A11) and FLD.
One study, using whole blood samples14 included 4525 indi-
viduals from four population-based cohort studies and the anal-
yses were adjusted for age, sex, smoking status, physical activity 
levels, alcohol intake and BMI. DNA methylation was assessed 
at over 400 000 CpGs in whole blood or CD14 + monocytes 
using a commercial array. They identified 22 CpGs associated 
with hepatic fat in European ancestry and further performed 
Mendelian randomization analyses which supported the asso-
ciation of hypomethylation of cg08309687 (LINC00649) with 
NAFLD (P = 2.5 × 10−4). Another one study23 showed that pe-
ripheral blood-derived DNA hypermethylation at one CpG site 
(cg06690548) located in an intron of SLC7A11 may be associ-
ated with reduced risk of hepatic steatosis. Another study25 was 
conducted among 60 participants [(mild NAFLD (n = 39), ad-
vanced NAFLD (N = 21)], found that a total of 1777 genes were 
differentially expressed between mild and advanced NAFLD 
cases (q-value < 0.05) clustered into four modules. One of the 
modules formed a scale-free network containing four hub genes 
(PAPLN, LBH, DPYSL3 and JAG1) that were overexpressed in 
advanced NAFLD. Another module formed a random network 
and was enriched for genes that accumulate in the mitochondria 
and the other two modules did not form unambiguous network. 
Lastly, a study24 conducted among 178 individuals in Europe, 
also found that NAFLD is associated with methylation shifts 
relevant for the expression of three genes (NPC1L1, STARD 
and GRHL) involved in lipoprotein particle composition.
3.3 | Noncoding RNAs
MiRNAs are deregulated in NAFLD and have been proposed 
as useful biomarkers for the diagnosis and stratification of 
disease severity of NAFLD and NASH.5 We found 24 stud-
ies2,6-9,26-43 that investigated the association of miRNAs with 
FLD (Table 2). Of these, 13 studies used blood samples,6,26-36 
three studies used liver tissue2,37,38 and eight studies used both 
blood and liver tissue samples.7-9,39-43 In addition, the stud-
ies included population with Asian (n = 9), European (n = 7), 
North American (n = 6) and South American (n = 2) ancestries 
with mean age of 46.9 years old. Overall, data were available 
on 5288 participants, from which there were 1359 NAFLD 
cases, 819 NASH cases and 174 simple steatosis cases.
Overall, these studies reported 34 miRNAs associated 
with FLD (Table 3). Among these, miR-122 (n = 14), miR-
34a (n = 8), miR-192 (n = 4), miR-21 (n = 2) and miR-99a 
(n  =  2) were associated with FLD in two or more inde-
pendent studies. Other studies reported that the following 
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T A B L E  3  Deregulated miRNA in liver tissue and blood circulation of participants with fatty liver disease
Liver tissue miRNAs Circulating miRNAs
miRNA Expression Phenotype Studies and years miRNA Levels Phenotype
Studies and 
years
miR-122 ↓ NAFLD and NASH Braza-Boïls et al, 
2016
miR-122 ↑ NAFLD Yamada et al, 
2013
↓ NAFLD Auguet et al, 2016 ↑ NAFLD and NASH Becker et al, 2015
↔ NAFLD Salvoza et al, 2016 ↑ NAFLD and FLD Raitoharju et al, 
2016
miR-34a ↑ NAFLD and NASH Braza-Boïls et al, 
2016
↑ NAFLD Abdel-Hamed 
et al, 2017
↔ NAFLD Salvoza et al, 2016 ↑ NAFLD Brandt et al, 2018
miR-125b ↓ NAFLD and NASH Sharma et al, 2013 ↑ NAFLD Hendy et al, 2019
miR-16-2 ↑ NAFLD and NASH Sharma et al, 2013 ↑ NASH and SS Pirola et al, 2015
miR-7-1 ↑ NAFLD and NASH Sharma et al, 2013 ↑ NAFLD and NASH Liu et al, 2016




↓ NAFLD and NASH Braza-Boïls et al, 
2016
↔ NAFLD Delik et al, 2020
miR-132 ↓ NAFLD and NASH Estep et al, 2010 ↑ NAFLD Akuta et al, 2020
miR-150 ↓ NAFLD and NASH Estep et al, 2010 ↑ NAFLD and NASH Ezaz et al, 2020
miR-433 ↓ NAFLD and NASH Estep et al, 2010 miR-34a ↑ NAFLD Yamada et al, 
2013
miR-28-3p ↓ NAFLD and NASH Estep et al, 2010 ↔ NAFLD and NASH Celikbilek et al, 
2014
miR-511 ↓ NAFLD and NASH Estep et al, 2010 ↑ NAFLD Muangpaisarn 
et al, 2017
miR-517a ↓ NAFLD and NASH Estep et al, 2010 ↑ NAFLD and NASH Liu et al, 2016
miR-671 ↓ NAFLD and NASH Estep et al, 2010 ↑ NAFLD Salvoza et al, 
2016
↑ NAFLD Hendy et al, 2019
↑ NAFLD and NASH Ezaz et al, 2020
miR-21 ↑ NAFLD Yamada et al, 
2013
↑ NAFLD and NASH Becker et al, 2015
miR-451 ↑ NAFLD Yamada et al, 
2013
miR-192 ↑ NAFLD and NASH Becker et al, 2015
↑ NASH and SS Pirola et al, 2015
↑ NAFLD and NASH Ezaz et al, 2020
↓ NAFLD Hu et al, 2020
miR-103 ↑ NAFLD Xu et al, 2015
miR-
331-3p
↓ NAFLD Zarrinpar et al, 
2016




↑ NAFLD and FLD Raitoharju et al, 
2016
miR-29b ↑ NAFLD He et al, 2019
(Continues)
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miRNAs including miR-451, miR-103, miR-855-5p, miR-
331-3p, miR-30c, miR-29b, miR-125b,miR-16, miR-7-1, 
miR-29c-3p, miR-33b*, miR-132, miR-150, miR-433, miR-
28-3p, miR-511, miR-517a, miR-671, miR-181d, miR-197, 
miR-146b, miR-10b, miR-29a, miR-19a, miR-19b, miR-375, 
miR-20a, miR-27a and miR-200a were also linked to FLD.
MiR-122 is abundant in liver and its function has been 
extensively studied.44 Most of the studies (n = 14) included in 
this review reported that miR-122 was associated with FLD 
and could be used as biomarker for FLD. Among these, 12 
studies6,7,9,26,28-32,34,35,40 were measured in blood samples. 
Among eleven of these studies indicating that miR-122 was 
upregulated in participants with FLD, only one study35 found 
no significant association between circulating miR-122 and 
participants with NAFLD. Three studies2,7,38 were performed 
using liver tissue, from which two of these studies2,38 found 
that miR-122 was downregulated in participants with fatty 
liver disease compared to healthy controls, and one study7 
found that the level of miR-122 did not significantly differ 
between participants with NAFLD and healthy controls. 
However, the receiver operating characteristic (ROC) curve 
analysis revealed that miR-122 could be a potential marker for 
discriminating NAFLD patients from healthy controls with 
an area under the curve (AUC) value of 0.858.7 Moreover, 
a two-stage study,40 investigating a large panel of circulat-
ing miRNAs at different phases of NAFLD, showed that 
circulating miR-122 was increased by 7.2-fold in participants 
with NASH vs healthy controls and 3.1-fold in participants 
with NASH vs simple steatosis.
MiR-34a is weakly expressed in hepatocytes, but 7 stud-
ies reported that circulating miR-34a in blood was signifi-
cantly upregulated in participants with FLD. One study9 
conducted among 40 Turkish participants, showed that 
circulating miR-34a was not significantly associated with 
NAFLD or NASH. Another study7 conducted among 64 
American participants, found that the level of miR-34a did 
not significantly differ between participants with NAFLD 
and healthy controls, but ROC curve analysis revealed that 
miR-34a could be a potential marker for discriminating 
NAFLD patients from healthy controls with an AUC value 
of 0.781.
MiR-192 was reported by three studies26,40,43 showing 
that circulating miR-192 is upregulated in participants with 
NAFLD, NASH or simples steatosis than healthy controls, 
only one study36 suggested that serum expression of miR-
192-5p in patients with acute pancreatitis and NAFLD is 
significantly down-regulated compared to acute pancreatitis 
patients without NAFLD and healthy controls.
Of note, two studies6,27 have also reported miRNAs to 
be used as therapeutic targets for the treatment of fatty liver 
disease without any general overlap between them. One 
study6 reported that miR-34a plays a role of physiological 
Liver tissue miRNAs Circulating miRNAs
miRNA Expression Phenotype Studies and years miRNA Levels Phenotype
Studies and 
years
miR-20a ↓ NAFLD Ando et al, 2019
miR-27a ↓ NAFLD Ando et al, 2019
miR-181d ↓ NAFLD and NASH Celikbilek et al, 
2014
miR-99a ↓ NAFLD and NASH Celikbilek et al, 
2014
↓ NAFLD Hendy et al, 2019
miR-197 ↓ NAFLD and NASH Celikbilek et al, 
2014
miR-146b ↓ NAFLD and NASH Celikbilek et al, 
2014
miR-10b ↓ NAFLD and NASH Celikbilek et al, 
2014
miR-29a ↓ NAFLD and NASH Celikbilek et al, 
2014
miR-200a ↑ NAFLD and NASH Ezaz et al, 2020
miR-19a ↑ NASH and SS Pirola et al, 2015
miR-19b ↑ NASH and SS Pirola et al, 2015
miR-375 ↑ NASH and SS Pirola et al, 2015
Abbreviations: FLD, fatty liver disease; miRNAs, microRNAs; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; SS, simple steatosis.
T A B L E  3  (Continued)
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significance in the biology of NAFLD and may present a 
therapeutic target for NAFLD. The other study27 reported 
that miR-103 may be a link between insulin resistance and 
NAFLD and could be used as a therapeutic target for the 
treatment of NAFLD.
Additionally, lncRNAs that cover a significant portion of 
noncoding transcriptome in mammalian genomes, regulate 
critical aspects of the genome biology.10 However, the role 
of genomic regions encoding lncRNAs in the risk of FLD 
remains largely unexplored. We identified only one study45 
that conducted among 486 individuals and hypothesized 
that variants in lncRNAs could influence the susceptibility 
to NAFLD. These findings suggested that genetic variation 
at rs2829145 in lnc-JAM2-6 may contribute to the disease 
severity.45
3.4 | Histone modification
We did not identify any study investigating the association 
of histone modification with fatty liver disease on humans. 
Future studies should elucidate whether histone modifica-
tions play any possible role in the physiopathology of fatty 
liver disease as well as in disease prognosis and treatment.
4 |  DISCUSSION
The present study aimed to provide a comprehensive review 
of the currently available evidence on the role of epigenetic 
modifications in FLD. Of the 36 included publications, the 
majority of the studies focused on association of miRNAs 
with NAFLD and some had a well-conducted cohort study 
design, with different tissues and analytical approaches. 
These results provide substantially support the existence of 
association between epigenetic alterations and risk of FLD. 
Yet, due to the small sample size, these findings should be 
interpreted with caution.
Overall the findings of this review suggest no consis-
tent associations with FLD in the studies of the global DNA 
methylation. Global DNA methylation provides an assess-
ment of DNA methylation levels in the evaluated tissue sam-
ple by quantifying the methylcytosine (5-mC) present in the 
genome.15 One study16 identified MT-ND6 methylation was 
higher and the other study17 identified LINE-1 was hypometh-
ylated in the livers of participants with NASH compared to 
participants with simple steatosis or normal livers. Liver 
MT-ND6 mRNA expression was significantly decreased in 
NASH patients and the status of liver MT-ND6 methylation in 
NASH group was inversely correlated with the level of regu-
lar physical activity. Hepatic methylation and transcriptional 
activity of the MT-ND6 are associated with the histological 
severity of NAFLD. This suggests that epigenetic changes of 
mtDNA could be potentially reversed by interventional pro-
grams, and physical activity could modulate the methylation 
status of MT-ND6. Moreover, LINE-1 may induce genetic 
variation and polymorphism through the recombination and 
rearrangement as well as through endogenous mutagenesis, 
thereby influencing the expression status of genes.
Associations of gene-specific DNA methylation (can-
didate-based approach) with FLD were explored in a few 
studies and without was found between the significant genes 
differentially methylated on studies that used this approach. 
Moreover, two EWAS14,23 conducted among 5975 partici-
pants which reported an association between cg06690548 
(SLC7A11) and FLD. Compared to candidate-based ap-
proach examine DNA methylation at specific CpG sites or 
regions, EWAS are typically hypothesis-free and screen up to 
hundreds of thousands of locus across the genome to identify 
CpGs or regions associated with FLD. In contrast, candidate 
gene DNA methylation analyses target loci in a limited num-
ber of specific genes, based on a priori hypotheses in small 
sample sizes. The majority of candidate gene studies did not 
adjust for confounders. There are also some limitations need 
to be considered on EWAS. Some studies using an EWAS 
approach in whole blood samples for quantification of DNA 
methylation might have missed CpG sites that are expressed 
only in other tissues such as liver.
In this systematic review, most of the epigenetic studies 
(n = 24) focused on miRNAs and fatty liver disease, but only 
13 studies2,9,26,30,33-35,37-41 were adjusted or matched for the 
relevant confounders. In line with a previous meta-analysis,5 
our findings suggest an inconsistent or even inverse correla-
tion of the direction of miRNA expression between blood 
or serum samples and liver tissue samples. For instance, 
serum miR-122 was always upregulated in participants with 
NAFLD or NASH vs healthy controls,6,26,30,31,40 but it was 
unchanged in liver tissue7 or even downregulated in liver tis-
sue.2,38 Serum miR-34a level was upregulated in participants 
with NAFLD or NASH vs healthy controls,6-8,41 but it was 
unchanged in liver tissue.7
Additionally, a small set of studies included in this review 
suggested that miRNAs could be used as potential therapeutic 
targets of FLD. miRNA-based therapeutics include miRNA 
mimetics, anti-miRNA oligonucleotides and exosomes 
loaded with miRNAs.46 Although no miRNAs are in clinical 
trials for FLD, a few are already in trials for viral hepatitis 
which may lead to FLD and liver cancer. For instance, sev-
eral miRNA-targeted therapeutics have reached clinical de-
velopment, including molecules targeted at miR-122, which 
reached phase II trials for treating hepatitis C,47 and a mimic 
of the tumour suppressor miRNA miR-34, which reached 
phase I clinical trials for solid tumours (eg liver).48
The current evidence reveals that several differentially meth-
ylated sites, such as cg06690548 annotated to SLC7A11 gene 
associated with FLD. Most of the CpG sites were involved in 
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lipid metabolism through inducing the expression of lipid-re-
lated genes, but one EWAS showed the FLD associated CpG 
sites also relation with glucose metabolism.14 Moreover, miR-
122, miR-34a and miR-192 may play a role in the development 
of FLD, but the quality of these studies should be considered 
for interpreting the findings. There are several components that 
determine the quality of the studies, such as design, sample 
size, use of tissue, confounder adjustment and replication.
Epigenetic modifications are relatively stable alterations 
that can explaining the effect of environmental factors on phe-
notype, and part of the missing heritability of common dis-
eases such as fatty liver disease, which is not accounted for by 
common genetic variants.4 The study of epigenetic markers is 
emerging as one of the most promising molecular strategies 
for diagnosis and treatment of FLD. Peripheral blood is easy to 
access and reflects multiple metabolic and inflammatory path-
ways. Therefore, methylation profiling in peripheral blood and 
noncoding RNAs to identify FLD is of great interest since sev-
eral epigenetic-based drugs and diagnostic biomarkers have 
entered clinical development. For example, clustered regularly 
interspaced short palindromic repeats (CRISPR), to modify 
the epigenetic control of gene expression for therapeutic pur-
pose has been vastly explored in the last decade.47 However, 
physiological changes as a consequence of increased physical 
activity and diet changes may also impact DNA methylation 
activity. For instance, increasing exercise and a low-carbohy-
drate diet may improve peripheral insulin resistance, therefore 
it may reduce the excess delivery of free fatty acids, glucose 
for free fatty acid synthesis to the liver, and may also impact 
patterns of DNA methylation.49
Collectively, current evidence suggests an association be-
tween epigenetic modifications and FLD. Yet, the available 
research is limited and hampered by small samples, subop-
timal designs and heterogeneity in approaches, analyses and 
tissues. Therefore, more research is needed in the future in 
order to draw stronger conclusions on the likely complex 
association between epigenetics and FLD and also decipher 
molecular pathway by which the epigenetic markers may reg-
ulate FLD. Specifically, more studies should examine global, 
candidate gene DNA methylation and histone modifications 
in large samples and these findings should be replicated in 
other populations. Furthermore, longitudinal studies and ge-
netic sensitive designs are needed to examine temporal re-
lation of epigenetics and their causal association with FLD.
5 |  CONCLUSIONS
In conclusion, promising results have been reported in 
the field of FLD and epigenetics, but still more basic and 
translational research is needed to understand the causal 
role of epigenetic modifications in FLD. These findings 
could pave the way for future studies and ultimately lead to 
targeted screening of high-risk individuals in clinical prac-
tice. This could be beneficial for both patient stratification 
for clinical trials, as well as prognostication and treatment 
when new therapies become available. Nonetheless, these 
findings should be considered cautiously given the sample 
sizes of the studies and statistical power, use of different 
target tissues, precluding solid causal inferences, lack of 
confounders adjustment and, replication in independent 
cohorts.
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